Doppelgerz® asset Vitamin E forte

Dosage form Application area Recommendations for use Contraindications Manufacturer
Read on
Certificate number:RU.77.99.11.003.Е.006679.08.14
Date of registration and renewal:14.08.2014
Dosage form: & nbspCapsules with a mass of 266.48 mg.
Classification "Composition" & nbsp Supplements - vitamins, vitamin-like substances and coenzymes
Classification "Clinical" & nbsp Supplements that primarily affect the processes of tissue metabolism BAD-source of monovitamins and vitamin-like substances Supplements of restorative action Supplements antioxidants Supplements that support the function of the cardiovascular system Supplements that promote the normalization of lipid metabolism Supplements that support the functions of the genitourinary system Supplements supporting the functions of the musculoskeletal system BAA to reduce the risk of functional disorders of female cyclic processes
Composition: & nbspComposition: D-alpha tocopherol, gelatin solution, gelatin, glycerol, purified water.
Scope: & nbsp
For realization to the population through the pharmacy network and specialized shops, departments of the trade network as a biologically active food additive - an additional source of vitamin E.
Suggested Usage: & nbspAdults and children over 14 years of age at 1 capsule per day with meals. Duration of admission is 1 month. After a break of 1 month, a second appointment is possible.
Contraindications:Individual intolerance to components, pregnant and lactating women.
Special instructions:Before use, consult a physician.
Shelf life:4 years.
Storage conditions:Store in a dry place at a temperature of no higher than 25 ° C.
Research protocols:
In exchange for the certificate of state registration No.RU.77.99.13.003.E.005334.05.14 dated May 13, 2014, the expert conclusion of the FBU of the Federal Target Program of the Federal Antimonopoly Service and the Federal Service for Supervision of Consumer Rights Protection No. 10-2 of FTs / 1266 of 28.03.2012, the protocol of laboratory studies of the AILTS FGBUC ЦГиЭ Rospotrebnadzor № 249 of March 17, 2014
Recipient:Kvayser Pharma, Open CompanyKvayser Pharma, Open Company Russian Federation
Information update date: & nbsp11.04.2016
Instructions
Up